Abstract Past research in Alzheimer's disease (AD) has largely been driven by the amyloid hypothesis; the accompanying neuroinflammation seen in AD has been assumed to be consequential and not disease modifying or causative. However, recent data from both clinical and preclinical studies have established that the immune-driven neuroinflammation contributes to AD pathology. Key evidence for the involvement of neuroinflammation in AD includes enhanced microglial and astroglial activation in the brains of AD patients, increased pro-inflammatory cytokine burden in AD brains, and epidemiological evidence that chronic non-steroidal anti-inflammatory drug use prior to disease onset leads to a lower incidence of AD. Identifying critical mediators controlling this neuroinflammation will prove beneficial in developing anti-inflammatory therapies for the treatment of AD. The type-I interferons (IFNs) are pleiotropic cytokines that control pro-inflammatory cytokine secretion and are master regulators of the innate immune response that impact on disorders of the central nervous system. This review provides evidence that the type-I IFNs play a critical role in the exacerbation of neuroinflammation and actively contribute to the progression of AD.
Introduction
The causation and propagation of Alzheimer's disease (AD) is a multistep process in which neuroinflammation plays an important role. The central nervous system (CNS) exhibits features of inflammation in response to injury, infection, or disease, whereby resident cells generate inflammatory mediators, including cytokines, prostaglandins, free radicals, complement factor, chemokines, and adhesion molecules, that stimulate recruitment of additional immune cells and activate astrocytes and microglia. This glial reactivity is initially beneficial and required for the efficient removal of the inflammatory stimulus and controlled return to physiological homeostasis; however, prolonged and dysregulated neuroinflammation can elicit deleterious effects on the central nervous system (CNS). The concept that neuroinflammation plays a role in the progression and exacerbation of neurodegeneration is one that is gaining credence, with recent data from both clinical and preclinical studies establishing that immune-driven neuroinflammation contributes to AD pathology. This review will analyse the role that the type-I interferons (IFNs) play in the control and regulation of neuroinflammation in chronic neurodegeneration.
Type-I IFN signalling cascades
Originally named for their ability to ''interfere'' with viral replication (Isaacs and Lindenmann 1957) , IFNs are a superfamily of pleiotropic cytokines associated with varied immunomodulatory functions related to host infection, pathogen and disease (de Weerd and Nguyen 2012) . There are three classes of IFNs based on their cognate receptor: type-I IFNs consisting of 14 subtypes, with the most & Peter J. Crack pcrack@unimelb.edu.au studied of these being IFNa and IFNb; type-II IFNs solely consisting of IFN-c; and type-III IFNs which contains three IFNk subtypes (de Weerd and Nguyen 2012) . These IFNs possess pro-inflammatory properties through the activation of a number of signalling pathways. Of these, the classical Janus-associated kinase (JAK) and signal transducer and activator of transcription (STAT) pathway (JAK-STAT) is the most critical and well defined (Platanias 2005) (Fig. 1) . Type-I IFN signalling occurs through their cognate receptor, the IFNa/b receptor (IFNAR) (de Weerd and Nguyen 2012) . The IFNAR is composed of two subunits, IFNAR1 and IFNAR2. Lacking intrinsic kinase activity, these subunits recruit JAKs to induce downstream phosphorylation. These are Tyk-2 and Jak1 for IFNAR1 and IFNAR2, respectively. These residues act as docking sites for the phosphorylation of a number of STATs, which upon phosphorylation translocate to the nucleus, resulting in proinflammatory gene transcription of interferon-regulated genes (IRGs) (Platanias 2005) . A number of IFN-regulated factors (IRFs) are also able to bind to the STAT complex prior to nuclear translocation. Of importance is IRF7, which is crucial in the autocrine production and exacerbation of the type-I IFN response (Honda et al. 2005) . Type-I IFN signalling is plastic in nature with over 2000 activated or repressed from ligand-receptor interactions (Schreiber and Piehler 2015) . It is now important to note that IFNb is capable of inducing JAK-STAT independent of the IFNAR2 subunit, via interaction with IFNAR1 alone (de Weerd et al. 2013) . Indeed, much remains unknown regarding the diverse biological outcomes of type-I IFN signalling (Ng et al. 2016 ).
Type-I IFN CNS toxicity
The complexity of type-I IFN signalling, and the differential effects it has in the central and peripheral nervous systems, ultimately leads to different outcomes. It is known that interferons play important roles in a number of physiological processes apart from antiviral and antimicrobial defence, with processes such as cell survival and immunomodulation requiring a low level of tonic type-I IFN release (Gough et al. 2012) . In multiple sclerosis (MS), an autoimmune disease leading to demyelination and peripheral motor neurodegeneration, IFNa and IFNb have been used as an effective therapy for reducing attacks in secondary progressive cases of the disease (Wingerchuk and Carter 2014) . Interestingly, IFNb has been shown to be a major driver of microglial phagocytosis of myelin in a murine autoimmune encephalitis (EAE) model suggesting that microglial generated IFNb is of benefit in combating the progression of MS (Kocur et al. 2015) . However, while these therapies have been beneficial in reducing the severity of the symptoms of MS, an epidemiological study has shown that there have been cases of IFNb treated MS patients developing Parkinson's disease (PD)-like symptoms following ongoing type-I IFN therapy (Manouchehrinia and Constantinescu 2012). These include common symptoms such as impaired motor function, as well as other cognitive deficits and depression. In the murine EAE model of MS, elevations in microglial and brain-infiltrating leukocyte IRF7 expression have been reported and indicate an increased capacity for brain type-I IFN production (Salem et al. 2011) . Furthermore, genomewide association analyses within these models have revealed a type-I IFN-dependent up-regulation of pro-inflammatory genes in brain-residing astrocytes alongside anti-inflammatory activity in the periphery (Rothhammer et al. 2016) . This illustrates that while the IFNs may be beneficial in the periphery, entry into the CNS, and their activity within this tightly regulated environment can be detrimental and exacerbate the degeneration of healthy neurons, leading to the development of many neurodegenerative disorders. Clearly, the regulation of IFN production and specificity in type-I IFN signalling in the CNS is of importance. This concept is highlighted by the studies of Ejerskov and colleagues who reported that the absence of IFNb led to Lewy body and PD like symptoms in the IFNb -/-mouse (Ejlerskov et al. 2015) . In contrast, the work of Main and colleagues proposes that blocking type-I IFN signalling, by genetic and pharmacological means, leads to a neuroprotection in the MPTP-toxin model of PD (Main et al. 2016a, b) . This seeming contradiction underscores our limited understanding of how type-I IFNs function in specific pathological contexts.
An increasing body of evidence suggests that accumulation of IFN within the brain leads to cellular toxicity and deleterious phenotypes. Transgenic mice that overexpress IFNa in glial cells show brain pathology and behavioural deficits such as Wallerian degeneration of myelinated fibres, alterations in synaptic strength and plasticity, increased seizure activity, and impaired learning ability (Campbell et al. 1999) . In addition, when IFN repressors such as SOCS1 are inactivated in mouse models, the mice die from excessive inflammation driven by IFNs (Alexander et al. 1999) . Ubiquitin-specific peptidase 18 (USP18) has recently been shown to be a key negative regulator of type-I IFN signalling. USP18 deficiency leads to severely enhanced IFN-induced inflammation which results in neuronal calcification and polymicrogyria (Meuwissen et al. 2016) . Increased expression of IFNa in the brain and cerebrospinal fluid (CSF) is also associated with cognitive decline in patients with human immunodeficiency virus (HIV) encephalopathy (Rho et al. 1995) . The 'sickness behaviours' that accompany West Nile virus infection have been associated with increased CNS-residing IFNb (Cunningham et al. 2007 ). Moreover, the neonatal AicardiGoutières syndrome is associated with excessive IFNa production in the CSF and serum, resulting in calcification of the basal ganglia and white matter, demyelination, and brain atrophy (Crow et al. 2006a, b) . The type-I IFN response has also been implicated in ageing, with genomewide analysis showing that the choroid plexus, an interface between the brain and circulation, displays a type-I IFN expression profile in both aged mice and humans (Baruch et al. 2014) . Furthermore, this study showed that inhibition of the type-I IFN signalling restored cognitive function in these mice. Based on the aforementioned evidence, prolonged type-I IFN exposure in the CNS appears to contribute to a myriad of neurodegenerative disorders.
Neuroinflammation in Alzheimer's disease (AD)
Pathologically, AD is primarily characterised by the loss of pyramidal neurons and synapses in the cerebral cortex and certain subcortical regions, in particular the hippocampus, resulting in gross atrophy of the brain and expansion of ventricular volume. Postmortem histological examination also reveals two distinctive lesions in AD-affected individuals, neurofibrillary tangles (NFTs), and senile plaques (SPs) (Selkoe 2001) . NFTs are composed of intracellular hyper phosphorylated aggregates of the microtubule associated protein tau, whilst SPs consist of extracellular deposits of amyloid-b (Ab) aggregates. These aggregates contain a number of Ab peptide species comprising between 37-43 amino acids, with the most abundant being Ab1-42 (Borchelt et al. 1997) . The deposition of Ab is considered to occur prior to elevated tau hyper-phosphorylation and decades before AD cognitive symptoms become apparent (Jack et al. 2013) . Giving this pathological timing event intervening with Ab production within early stages of disease proposes an attractive therapeutic window in support of the amyloid hypothesis. Alongside amyloidosis, neuroinflammation has been implicated throughout the progression of AD. Initially, the coordinated neuroinflammatory response to Ab seeding is required for efficient microglial-mediated phagocytic removal and astrocytic-mediated enzymatic breakdown of amyloid peptides to maintain healthy brain function. Excessive Ab deposition and NFTs in AD impair the Abrelated clearance abilities of recruited microglia and astrocytes that manifests as a chronically dysregulated neuroinflammatory phenotype (Eikelenboom et al. 2006; Minter et al. 2016b ). This impaired clearance results in continued microglial stimulation and excessive pro-inflammatory cytokine production. Heightened levels of inflammatory cytokines levels are able to cause degeneration and death of otherwise healthy proximal neurons, directly contributing to AD pathology (Minter et al. 2016b ). In addition, release of cellular debris and damage associated molecular patterns by these degenerating neurons can further stimulate microglia and inflammatory mediator production. As such, this neuroinflammatory process has the potential to become self-perpetuating, with removal of the initial Ab stimulus unlikely to produce a resolution (Heneka et al. 2013) .
Further evidence for the contribution of neuroinflammation in AD pathology includes a number of long-term epidemiological studies of individuals prescribed nonsteroidal anti-inflammatory drugs (NSAIDs). Reviews of both prospective and retrospective studies demonstrate that individuals administered NSAIDs display a lower prevalence of AD compared to respective controls and this occurrence is strongly related to the length and time of commencement for therapy (Imbimbo et al. 2010 ). In particular, numerous epidemiological studies have demonstrated that individuals taking these drugs prior to age of onset periods can halve their risk of developing AD (Vlad et al. 2008; Zandi et al. 2002; in t' Veld et al. 2001 ). Contrary to these epidemiological studies, interventional use of NSAIDs in the treatment of clinically diagnosed AD has failed to display patient efficacy thus far (Group et al. 2007 (Group et al. , 2008a . These clinical observations suggest that modulation of neuroinflammation prior to or early in AD progression may alleviate disease severity; however, this therapeutic window narrows significantly in latter stages.
Cytokine systems mediating microglial activity in AD Pro-inflammatory cytokines secreted in AD not only induce neuroinflammatory and neuropathic mechanisms but also influence classical neurodegenerative pathways such as amyloid precursor protein (APP) processing. For example, interleukin-1b (IL-1b) can regulate APP processing and Ab production in vitro (Blasko et al. 1999) , and conversely, Ab induces a range of pro-inflammatory mediator secretion in cultured microglia (Floden and Combs 2006; Hanisch 2002) . Together, Ab-stimulated production of pro-inflammatory mediators and their feedback activation of APP processing (Sastre et al. 2003 (Sastre et al. , 2006 contribute to a selfperpetuating, vicious cycle. In this manner, postmortem analyses of AD-affected individuals reveal that microglia are skewed to a pro-inflammatory phenotype (Sudduth et al. 2013 ) and remain inefficient in Ab phagocytosis and clearance (Mosher and Wyss-Coray 2014) . Considering these observations, identifying mechanisms that alleviate the pro-inflammatory activity of microglia or perhaps promote anti-inflammatory phenotypes may provide a novel means of AD therapy.
A number of in vivo studies have investigated the modulation of pro-inflammatory cytokine systems in various mouse models of AD. Increased levels of TNFa, IL1b, and IL-6 in the APP SWE/ PS1 M146L mouse model skew microglia to a pro-inflammatory phenotype (Patel et al. 2005) . Either removal or inhibition of iNOS in APP SWE / PS1 DE9 mice shifts microglia from an activated pro-inflammatory state to an anti-inflammatory phenotype, resulting in decreased levels of Ab. Subsequent behavioural analysis of these mice revealed a rescue from the induced cognitively impaired AD phenotype (Kummer et al. 2011 ). Deletion of tumour necrosis factor death receptor (TNFR1), the endogenous receptor for TNFa, in APP 23 mice leads to decreased levels of Ab as well as diminished levels of microglial activation (He et al. 2007) . Ab can stimulate IL-1b production by activating the NALP3 inflammasome expressed in neural tissue (Halle et al. 2008) . Activating the NALP3 inflammasome also directly contributes to amyloid load, constrained microglial Ab phagocytosis, and behavioural deficits in APP SWE / PS1 DE9 mice (Heneka et al. 2013) . In contrast to the aforementioned studies, hippocampal injections of an adeno associated virus (AAV) expressing IL-b into APP SWE /PS1 DE9 mice lead to increased numbers of arginase-1 (ARG-1) positive microglia with increased levels of the anti-inflammatory marker ARG-1 shown to be able to clear Ab plaques (Cherry et al. 2015) . These studies support the notion that timing of inflammatory interventions in the potential treatment of AD is of utmost importance and drastically alters disease phenotype.
Additional in vivo studies investigating the effects of modulating hallmark anti-inflammatory cytokine systems in preclinical AD models have been contrasting. Using an AAV to deliver IL-4 or IL-10 to hippocampal regions of APP SWE /PS1 M146L mice, reductions in microgliosis and improvements in cognition have been reported (Kiyota et al. 2010) . A decrease in Ab levels is also seen in AAV delivery of IL-4 to the hippocampus of these mice (Kiyota et al. 2012) . Contrary to these studies, Chakraborty et al. (2015) has demonstrated that AAV delivery of IL-10 via intra-cerebroventricular (ICV) injection into multiple APP transgenic models (TgCRND8 and Tg2576 mice) confers alleviated amyloidosis, worsened cognitive deficits, and reductions in microglial-mediated Ab phagocytosis. Furthermore, genetic ablation of IL-10 in APP SWE /PS1 DE9 mice confers enhanced microglial Ab clearance resulting in attenuated amyloidosis (Guillot-Sestier et al. 2015) . Similar discrepancies have been observed in findings regarding the anti-inflammatory cytokine TGFb. In APP SWE/V717F transgenic mice containing up-regulated astrocytic expression of TGFb, decreased Ab levels in parallel with increases in overall microglial activation have been reported (Wyss-Coray et al. 2001 ). However, blockade of TGFb signalling in innate immune cells of Tg2576 mice facilitated the infiltration of Ab-clearing peripheral macrophages and significantly reduced amyloid burden (Town et al. 2008) . These seemingly conflicting studies highlight the complexity of anti-inflammatory cytokine signalling in AD models of amyloidosis but also re-enforce the importance of the peripheral immune response, not just microglial reactivity, in driving neuroinflammation. Ongoing studies are now focused on identifying how genetic variants in these anti-inflammatory cytokines confer altered risk for the onset of AD in numerous demographic populations (Di Bona et al. 2012; Li et al. 2014; Luedecking et al. 2000; Su et al. 2016) .
The emergence of microglia as an important cell type in the regulation of the inflammatory environment in the CNS has led to various terminology being adopted to describe their activation states. Microglial cells of the brain are derived from yolk sac-localised macrophage progenitors that invade the brain at very early embryonic stages (Alliot et al. 1999; Kierdorf et al. 2013 ). This developmental lineage and the ability of microglia to respond to injury or inflammation by performing phagocytosis and producing cytokines and chemokines have led them to be categorised as 'resident macrophages' by many researchers. This categorisation has meant that they are often delineated into the pro-inflammatory or M1 camp or the anti-inflammatory or M2 camp. This M1/M2 delineation has been used for ease of identification of the function of microglial cells.
However, description of peripheral macrophages has moved past the M1/M2 delineation (Murray and Wynn 2011; Murray et al. 2014) . Like most CNS processes, an 'all or nothing' delineation has led to confusion over the nomenclature of microglial polarisation, when this very polarisation phenomenon itself is in the early stages of research. It is known that microglia exist in a spectrum of activation states as recent transcriptomic analysis suggests that microglial function and phenotype are influenced by brain region, age, and microenvironment (Wes et al. 2016) . In a recent review, Ransohoff (2016b) mounts a persuasive argument that the M1/M2 categorisation is one that hinders the field of microglial research and is best discarded as an outdated hypothesis.
Interplay of amyloidosis and type-I IFN-mediated neuroinflammation
Crucially, type-I IFN signalling is involved in the initiation and regulation of all the aforementioned Ab-stimulated pro-inflammatory cytokine systems . In recent years, our laboratory has focused on investigating how type-I IFN signalling shapes the neuroinflammatory landscape in AD. We have demonstrated that soluble Ab1-42 initiates a type-I IFN response in neurons in vitro, and, importantly, that this response occurs prior to the upregulation of other pro-inflammatory cytokines (Taylor et al. 2014 ). This preliminary evidence supports the notion that an amyloid-induced type-I IFN response may be an early stage critical component in the development of neuroinflammation in response to Ab insult.
Our analysis of human postmortem AD patients reports an up-regulation of hallmark pro-inflammatory cytokines and type-I IFNs (Taylor et al. 2014) . This finding suggests that type-I IFNs are mediators released during neuroinflammatory cascades and highlights their potential to contribute to AD pathology. This up-regulation of type-I IFN expression coincided with elevated pre-frontal cortical IRF-7 expression, crucial for type-I IFN production, suggesting an increased type-I IFN production capacity in diseased patients. Taken together with findings presented in primary cultured IFNAR1 -/-neurons and glia and the APP SWE /PS1 DE9 9 IFNAR1 -/-mouse (discussed below), it is likely that this type-I IFN response is perpetuating a deleterious neuroinflammatory cycle and actively contributing to disease progression (Minter et al. 2016a) . The hypothesis that type-I IFNs facilitate deleterious neuroinflammation and contribute to neurodegeneration is supported by further findings implicating a deleterious role of type-I IFN signalling on hippocampal neurogenesis and brain function in response to ageing (Baruch et al. 2014; Zheng et al. 2014 ).
Type-I interferon pathway in neuroinflammation and neurodegeneration: Focus on Alzheimer's… 801
Comprehensive analysis of APP SWE /PS1 DE9 mice reveals a positive correlation between age, pro-inflammatory cytokine burden (including type-I IFNs), and cognitive decline (Francois et al. 2014) . These preclinical analyses support the notion that neuroinflammatory severity may be a true correlate of cognitive decline in AD (Heneka et al. 2015; Ransohoff 2016a; Latta et al. 2015) . As previously described, the neuroinflammatory response is multi-faceted and the exact cell-type-specific contributions to its propagation in AD remain unclear. Our investigation of type-I IFN signalling mechanisms revealed a neuronal contribution to neuroinflammation in the APP SWE /PS1 DE9 mouse by which phosphorylation of Stat-3 was co-localised with FOX-3 (NeuN) using immunohistochemical techniques (Minter et al. 2016a ). In addition, type-I IFN response genes are up-regulated in the choroid plexus of the J20 mouse model of AD and epithelial cells isolated from this tissue exhibit an IFNa response to soluble Ab1-42 challenge (Mesquita et al. 2015) . These findings identify that whilst astrocytes and microglia are considered the primary mediators of CNS neuroinflammation, other brain-residing cell types should not be overlooked. Indeed, removal of type-I IFN signalling in neuronal cultures is protective against amyloid insult (Taylor et al. 2014 ) implicating the importance of neuronal type-I IFN signalling in the response to neurotoxic Ab peptides.
The neuroprotection seen in IFNAR1 -/-neurons to Ab peptides led us to cross the IFNAR1 -/-mouse with the APP SWE /PS1 DE9 to generate the APP SWE /PS1 D-
-/-mouse, a murine model of AD lacking type-I IFN signalling. We found that although there was no alteration in amyloid plaque deposition and only modest reductions in monomeric Ab load, there was improved spatial cognitive performance as measured by the Morris water maze test (Minter et al. 2016a ). These mice also displayed a predominantly anti-inflammatory glial phenotype which was confirmed with in vitro studies which demonstrated that Ab1-42-conditioned media from IFNAR1 -/-glia was significantly less toxic to primary cultured neurons than the corresponding wildtype glia media, suggestive that type-I IFN signalling is required in the neurotoxic response to Ab1-42. It is important to note that our investigation into the neuroinflammation driving an AD-like phenotype in aged APP SWE /PS1 DE9 mice and in AD itself does not discredit the amyloid cascade hypothesis. Rather, our findings reported in Taylor et al. (2014) and Minter et al. (2016a) support amyloidosis as a trigger of type-I IFN-mediated neuroinflammation that, in a chronically active setting, drives further neurodegeneration and contributes to AD progression.
These findings also suggest that alleviating neuroinflammation, specifically through modulation of type-I IFN signalling, may delay cognitive decline and reduce neurotoxicity irrespective of Ab load. Neurons produce and respond to type-I IFNs (Prehaud et al. 2005; Wang and Campbell 2005) , inducing pro-apoptotic signalling mechanisms (Hertzog et al. 1994) , that likely explain the type-IFN-mediated brain toxicity observed in overexpression models (Campbell et al. 1999) . As type-I IFNs are master regulators of hallmark pro-inflammatory cytokines that also induce neurodegeneration (Akassoglou et al. 1997; Kawai and Akira 2006; Thornton et al. 2006) , it is likely that blockade of type-I IFN signalling also prevents downstream hallmark cytokine-induced toxicity irrespective of amyloid load. Thus, there may still be therapeutic value in reducing inflammatory severity in AD despite the maintenance of amyloid burden.
A critical issue within the current field is identifying how Ab species are detected by the innate immune system to induce sustained neuroinflammation in AD. Investigation of the pattern recognition receptor sub-family, the Toll-like receptors (TLRs), highlights these first-line response entities of the innate immune system as prime candidates for Ab detection (Salminen et al. 2009; Minter et al. 2016b ). The majority of TLR signalling requires recruitment of the myeloid differentiation factor-88 (Myd88) adaptor protein that confers activation of pro-inflammatory nuclear factor kappa B and IRF dependent pathways (Barton 2007; Downes and Crack 2010) . We have demonstrated, through the use of Myd88 -/-, IRF7 siRNA knockdown (KD) and IRF3 KD neuronal cell culture systems, that the TLR network is involved in the initial production of type-I IFN in response to soluble Ab1-42 (Minter et al. 2015) . Furthermore, these genetically manipulated cultures display similar levels of protection against Ab1-42 toxicity when compared to the aforementioned neuronal cultures lacking type-I IFN signalling (Taylor et al. 2014) . Thus, we propose that Ab-TLR signalling, in part, drives the up-regulated type-I IFN production and signalling observed in our models of AD (Minter et al. 2015 (Minter et al. , 2016a Taylor et al. 2014) , maintaining significant implications for the propagation of neuroinflammation and neuronal toxicity in AD.
Juxtaposed to this proposal, in vivo studies targeting the regulation of TLR-Myd88 signalling in murine models of AD remain confounded. One study has demonstrated reduced amyloid pathology in APP SWE /PS1 DE9 mice upon genetic ablation of Myd88 (Lim et al. 2011) in contrast to other studies illustrating that TLR inhibition or removal of the Myd88 adaptor protein impedes the microglial ability to detect Ab and worsens disease pathology (Michaud et al. 2011 (Michaud et al. , 2013 . However, a more recent study suggests that Myd88 may not be a key entity in amyloid detection as genetic ablation of this TLR adaptor molecule in APP SWE / PS1 DE9 mice fails to influence amyloid deposition nor plaque-localised gliosis (Weitz et al. 2014) . We demonstrate that removal of Myd88 in primary cultured neurons confers protection against Ab1-42, correlating with an attenuated type-I IFN response (Minter et al. 2015) . Hence, further investigation into the precise mechanisms of Ab-TLR signalling resulting in cell-type specific type-I IFN production is required to unravel possible therapeutic targets.
Referenced evidence throughout this review suggests that Ab sensing by TLRs and subsequent IRF-mediated gene transcription can lead to the production of type-I IFNs. Of these IRFs, IRF-7 is a critical regulator of IFNa production in response to viral and bacterial infection (Honda et al. 2005) . It is of interest that IRF-7 is up-regulated in human AD postmortem brains alongside IFNa levels (Taylor et al. 2014) and that these levels are reduced in APP SWE /PS1 DE9 mice that lack type-I IFN signalling (Minter et al. 2016a ). In addition, Minter et al confirmed that the neuronal type-I IFN response to soluble amyloid is mediated primarily through the TLRs and that production is dependent upon Myd88 and IRF-7 signalling (Minter et al. 2015) . Hence, the IRF-7-dependent production of type-I IFN appears to be a critical element of the pro-inflammatory response to Ab both in vitro and in vivo. Interestingly, genetic variants of IRF7 and IFNa are prevalent amongst the human population, impacting directly on an individual's ability to fight infection from common pathogens (Lee et al. 2014) . Mutations in IRF7 have been linked to increased viral titres of Epstein Barr virus in AD patients (Licastro et al. 2015) , with CNS viral infection being a common comorbidity in AD (Porcellini et al. 2010; Licastro et al. 2011) . Furthermore, the natural ageing type-I IFN response is deleterious to neuronal function and can inhibit hippocampal neurogenesis (Baruch et al. 2014; Zheng et al. 2014) . Taken collectively, common genetic abnormalities in the IRF7-dependant type-I IFN production mechanism may pre-dispose individuals to initiate an excessive neuroinflammatory response to Ab and drive an AD phenotype. This hypothesis is supported by epidemiological studies concluding a strong correlation between the occurrence of a midlife neuroinflammatory event (hypertension, stroke, and brain trauma) and significantly elevated risk of late-onset AD (Faraco and Iadecola 2013; Iadecola 2014) .
Throughout this review, we propose that type-I IFNs are critical mediators of the neuroinflammatory response observed in AD. A key question arising from this hypothesis was: Are the type-I IFNs crucial for the activation of inflammatory responses themselves or are they regulators of subsequent inflammatory events? Data from our laboratory suggest the latter. By removing type-I IFN signalling in our in vitro (Taylor et al. 2014 ) and in vivo (Minter et al. 2016a) models of AD, we do not observe complete ablation of neuroinflammation, but an altered inflammatory environment is evident. First, primary cultured IFNAR1 -/-neurons and glia still initiate an IL-6 response to Ab1-42 insult similar to wild-type cells despite the absence of type-I IFN signalling (Taylor et al. 2014) . Second, whilst microgliosis is attenuated in APP SWE /PS1 DE9 9 IFNAR1 -/-mice, the recruitment and activation of these cells to plaque burdened areas was not completely ablated (Minter et al. 2016a ). Third, APP SWE /PS1 DE9 9 IFNAR1 -/-mice display increased astrogliosis and cortical IL-1b levels compared to APP SWE /PS1 DE9 alone (Minter et al. 2016a ). This enhanced astrocyte recruitment facilitated by IL-1b pro-inflammatory cytokine release in a largely anti-inflammatory environment clearly suggests that type-I IFNs are master modulators and/ or regulators of inflammation. This modulatory characteristic remains important as inflammation is required for effective Ab clearance from the CNS, it is only when this process becomes dysregulated and excessive that it contributes to neurodegeneration (Heneka et al. 2014 ). Data presented from the studies of Taylor et al. and Minter et al. implicate neuroinflammatory processes as key mechanisms by which Ab induces neuronal dysfunction and toxicity and associates type-I IFN signalling as a critical modulator of these mechanisms.
Conclusions
Our work and that of others provide strong evidence in implicating neuroinflammation as a key pathological mechanism contributing to the progression of AD. Specifically, the neuroinflammatory response to Ab is regulated by the type-I IFNs from the time of initial soluble amyloid detection through to later stages of disease in APP SWE / PS1 DE9 mice. This robust type-I IFN response is deleterious to neuronal viability and cognition and modulation of this IFNAR1-dependent signalling shows great promise in the development of novel anti-inflammatory therapy for the treatment of AD. We hypothesise that type-I IFN signalling is crucial in the regulation of the neuroinflammation in AD and other forms of dementia. If type-I IFN signalling can be regulated, then the avenue is open for a viable alternative strategy to reduce the neural cell death and subsequent cognitive decline in AD. A better understanding of the neuroinflammatory and immunoregulatory processes in the disease will aid the development of anti-neuroinflammatory approaches that may not cure AD, but may slow the progression or delay the onset of this devastating disorder.
